Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study

• Published in: Arthritis research & therapy Vol. 14; no. 2; p. R53
• Main Authors: Lekpa, Fernando Kemta, Poulain, Cécile, Wendling, Daniel, Soubrier, Martin, De Bandt, Michel, Berthelot, Jean Marie, Gaudin, Philippe, Toussirot, Eric, Goupille, Philippe, Pham, Thao, Sellam, Jérémie, Bruckert, Rémy, Paul, Muriel, Farrenq, Valérie, Claudepierre, Pascal
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 09.03.2012; BioMed Central
• Subjects: Adult; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - metabolism; Drug Delivery Systems - methods; Drug therapy; Female; Follow-Up Studies; Humans; Interleukin-6 - antagonists & inhibitors; Interleukin-6 - metabolism; Male; Middle Aged; Patient outcomes; Retrospective Studies; Spondylarthritis - drug therapy; Spondylarthritis - metabolism; Spondyloarthropathies; Treatment Outcome; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Tumor Necrosis Factor-alpha - metabolism
• ISSN: 1478-6354; 1478-6362; 1478-6354
• DOI: 10.1186/ar3766

The aim of this study was to evaluate, under real-life conditions, the safety and efficacy of tocilizumab in patients having failed anti-TNFα therapy for spondyloarthritis. French rheumatologists and internal-medicine practitioners registered on the Club Rhumatismes et Inflammations website were asked to report on patients given tocilizumab (4 or 8 mg/kg) to treat active disease meeting Assessment of SpondyloArthritis International Society (ASAS) criteria for axial or peripheral spondyloarthritis, after anti-TNFα treatment failure. Safety and efficacy after 3 and 6 months were assessed retrospectively using standardised questionnaires. Data were obtained for 21 patients, 13 with axial spondyloarthritis (46% men; median age, 42 years; disease duration, 11 years; HLA-B27-positive, 92.3%) and eight with peripheral spondyloarthritis (25% men; median age, 40 years; disease duration, 10 years; HLA-B27-positive, 62.5%). No patients with axial disease had at least a 20 mm decrease in the BASDAI, nor a BASDAI50 response or major ASAS-endorsed disease activity score improvements after 3 or 6 months; an ASAS-endorsed disease activity score clinically important improvement was noted at month 3 in five of 13 patients and at month 6 in one of four patients. A good DAS28 response was achieved in four patients with peripheral disease, including one in EULAR remission at month 3. Four patients were still taking tocilizumab at month 6, including one in EULAR remission and one with a good DAS28 response. Tocilizumab was well tolerated, with no serious adverse events. Initially elevated acute-phase reactants declined during tocilizumab therapy. In patients having failed anti-TNFα therapy, tocilizumab decreased acute-phase reactants but failed to substantially improve axial spondyloarthritis and was inconsistently effective in peripheral spondyloarthritis.